RNUGF   $0.092  -54.00% Market Closed


Current temperature:
ST: None, Cor:

Analyst Recommendations:
Number of estimates 1
Target Price Mean 2.85
Mean unverified/preliminary 2.85 / 2.85
Target Price Low / High 2.85 / 2.85
Median / STD DEV 2.85 / 0.00
ISIN GB00BF5G6K95
ceo Ms. Catherine Isted A.C.M.A.
Website https://www.reneuron.com
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.